drugset / Trial / NCT05211154
Evaluation of the Efficacy of Diclofenac Potassium and Rimegepant for the Acute Treatment of Migraine
RandomizedParallel-groupOpen-labelTreatment
Summary
In a real-world population of adults with migraine, the investigators would like to investigate whether 50 mg diclofenac potassium is non-inferior to 75 mg rimegepant in terms of pain freedom at 2 hours after drug intake.
Timeline
- Start
- 2022-05-05
- Primary completion
- 2025-04-30
- Completion
- 2025-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Diclofenac | Other / unclassified | 50 mg | Oral |
| Comparator | Rimegepant | Small molecule | 75 mg | Oral |